Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company Valo Health. The collaboration aims to leverage Valo Health’s patient genetic database, artificial intelligence (AI) capabilities, and tissue modelling platform for the target identification, discovery, and development of novel treatments for cardiometabolic diseases. Additionally, Novo Nordisk has in-licensed three of Valo’s pre-clinical candidates in cardiovascular diseases (CVDs), marking a significant step in expanding their pipeline for these conditions.
Financial Terms and Collaboration Scope
Under the terms of the partnership, Valo Health will receive an upfront payment of USD 60 million and is eligible for potential milestone payments up to USD 2.7 billion, in addition to an undisclosed amount allocated for research and development (R&D). The agreement also includes future royalties, highlighting the potential value of the collaboration and the anticipated outcomes.
Novo Nordisk’s Expanding Collaborations in 2023
According to Fineline Info & Tech data, Novo Nordisk has been active in forming collaborations this year, with partnerships established with Aspect Biosystems, Life Edit Therapeutics, and Eleven Therapeutics. These collaborations reflect Novo Nordisk’s commitment to exploring new scientific frontiers and advancing treatments for a range of diseases, including cardiometabolic conditions.-Fineline Info & Tech
